-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Evolving Standards of Care
-
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events
Industry Supported
The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education.
-
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 pandemic in how clinical trials are conducted, as well as the implications of these changes and what can be expected going forward. Q: How has…
-
COVID-19 and Thoracic Malignancies
Coronavirus disease-2019 (COVID-19) is a novel infectious disease, mainly affecting the respiratory tract, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). COVID-19 emerged in Wuhan, China, in December 2019 and rapidly escalated to become a global health crisis. Early reports on the prognosis of patients with cancer with COVID-19 were conflicting and limited.…
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies
Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration workshop identified many advantages to the neoadjuvant approach.3 Pathologic response after neoadjuvant therapies in resection specimens can serve as a surrogate endpoint for PFS and…
-
Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?
The absence of an OS benefit in more than 3 decades of clinical trials for extensive-stage SCLC (ES-SCLC) had become an all-too-familiar refrain among the introductions to numerous publications and grant applications. However, within the past 2 years, the publication of two landmark studies of immune checkpoint inhibitors (ICIs) in combination with frontline chemotherapy for…
-
Liquid biopsy for early lung cancer detection and cancer interception
By Christian Rolfo, MD, PhD, MBA, Dr.hc. Over the past several years, three large randomized clinical trials demonstrated that low-dose computed tomography (LDCT) screening is a valuable method for lung cancer screening in high-risk individuals and can significantly reduce lung cancer mortality.1-3 Economic costs, technical and organizational requirements, exposure to not negligible radiation doses, the…
-
Telehealth: Bridging the Digital Divide Is Still a Work In Progress
By Sandip Pravin Patel, MD, and Martin Edelman, MD Posted: August 21, 2020 Dr. Sandip Pravin Patel Dr. Martin Edelman COVID-19 has drastically affected medicine and broader society. With physical distancing necessitating the need to overcome limitations in prevention and treatment, telehealth has become…
-
Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. However, approximately 20% to 30% of patients with metastatic NSCLC have an oncogene-driven disease, for which targeted therapies with mutation-specific tyrosine kinase inhibitors (TKIs) are…
-
Bringing Telehealth to the Front Lines of Lung Cancer Care in the COVID-19 Pandemic
By Luis E. Raez, MD, FACP, FCCP Posted: August 21, 2020 Our current electronic medical records (EMR) are equipped with telehealth capability. Some of us have spent the last 2 to 3 years working on the implementation of this field in our cancer practices. However, during that time, the enthusiasm from doctors and patients was…
-
Conducting a Lung Multidisciplinary Tumor Board at the National University Cancer Institute, Singapore
By Ross Soo, MB, BS, PhD, FRACP Posted: August 21, 2020 Dr. Ross Soo Impressive progress has been achieved in many aspects of lung cancer. Over the past decade, advances have occurred in multiple areas including diagnostic radiology, interventional pulmonology and radiology, molecular pathology, radiation therapy, minimally invasive surgery, immunotherapy and molecular-targeted therapy.…
-
Patient Perspectives on Telehealth During COVID-19: Balancing Fear, Self-Advocacy
By Jennifer Byrne Posted: August 21, 2020 For nearly 2 decades, Bonnie Anderson has defied incredible odds in the face of mesothelioma, hairy cell leukemia, breast cancer, lung cancer, and kidney cancer. “Since they can’t do anything about the mesothelioma or the kidneys or any of the tumors, I’m pretty much out of options until…
View ILCN Archives
Provider Resources
Popular Articles